Microsoft, Adaptive Biotechnologies Partner to Study Immune System Genetics | Latest News
Adaptive Biotechnology announced today that it has partnered with Microsoft to plan the genetics of the human immune system, with the goal of detecting cancers and other diseases in their early stages.
The partnership will combine Adaptive Immunization Sequencing technology with Microsoft's search and large-scale machine learning and cloud computing capabilities. The collaborators intend to develop diagnoses of individual diseases at the beginning, and finally develop a diagnosis of universal disease from a single blood test.
Under the terms of the agreement, Microsoft also made an unspecified financial investment in Adaptive.
"This announcement reaches a turning point in the field of health and biotechnology, and now we have the technology to do what we have been talking about for the last decade: we developed a map of universal antigen [T cell receptor] that presents a opportunity to help patients on an unprecedented scale, "customizable president, CEO and co-founder Chad Robins said in a statement. "Some conditions such as cancer or autoimmune disorders can be difficult to diagnose, but this universal map of the immune system will allow an early and accurate diagnosis of the disease, which can help connect the points to understand the relationship between diseases."
Microsoft also noted that this collaboration is part of the Healthcare NExT initiative, which was launched last year to advance the use of artificial intelligence and cloud computing in the health field.
Last November, Adaptive announced a collaboration with Amgen to measure minimal residual disease in patients with multiple myeloma in a clinical trial, using its immune sequencing technology.
Comments
Post a Comment